Yervoy 5mg/ml Solution for Infusion
PDF Leaflet Revision Date: 24 July 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of previously treated unresectable or metastatic melanoma in adults.
Dosage (summary)
3 mg/kg IV over 90 mins every 3 weeks for 4 doses.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Corticosteroids
- Anticoagulants
Contraindications
- Hypersensitivity to ipilimumab or excipients
Common side effects
- Diarrhoea
- Rash
- Pruritus
- Fatigue
- Nausea
Counselling Points
- Monitor for immune-related adverse reactions
- Avoid during pregnancy
- Use contraception during treatment
Serious warnings
- Severe immune-mediated reactions
- Gastrointestinal perforation
- Hepatotoxicity
Important Disclaimer
The Yervoy 5mg/ml Solution for Infusion professional information leaflet below is the property of Equity Pharmaceutical and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
